This study carried out to investigate the effects of soybean fatty acids and soybean calcium salt fatty acids on broiler chicken performance, carcass yield, pancreas and abdominal fat percentage. A total of 500 commercial crossbred of Ross was examined in 5 treatments and arranged on a completely randomized design (CRD) with 4 replicates per each treatment. Twenty five chicks were placed in each pen. The experiment lasted for 49 days. Neither soybean fatty acids nor soybean calcium salt fatty acids were used during the experiment in the first treatment. In the second treatment, for starter, grower and finisher period 0, 2.5 and 5 percents of soybean fatty acids were included respectively. During the third treatment 0, 2.5 and 5 percents of calcium salt fatty acids were used respectively, but in the fourth treatment 2.5, 5 and 5 percents of soybean fatty acids were used respectively, and in fifth treatment within the same period, 2.5, 5 and 5 percents of calcium salt fatty acids were used respectively. The results of the statistical analysis showed that there were significant differences in feed intake, weight gain and feed conversion ratio during the whole rearing periods (P<0.05). The results also showed significant differences among all treatments for carcass yield as well as pancreas percentage (P<0.05), and the use of soybean fatty acids and soybean calcium salt fatty acids had no significant effects on abdominal fat. It can be concluded from the results that the use of soybean fatty acids has precedence over calcium salt fatty acids on broiler performance.

Omega-3 fatty acids have established beneficial effects for cardiovascular disease. The use of omega-3 supplements for patients with non-alcoholic fatty liver disease (NAFLD) was proposed. The purpose of this study was to review the relationship between omega-3 fatty acids intake and NAFLD. In this study, the terms such as NAFLD, omega-3 fatty acids, docosahexanoic acid, and eicosapentanoic acid were searched in PubMed search engine.15 studies on NAFLD and omega-3 were found. Four of these studies were not fully available. Three studies were not strong in terms of design. Therefore, 8 studies were chosen. The results showed that omega-3 is a regulator of gene expression in the liver. Human studies have established that consumption of omega-3 have a role in reducing the hepatic steatosis, improving insulin sensitivity and decrease the inflammatory marker. More clinical trials should be conducted to confirm these findings. Omega-3 fatty acids may improve symptoms associated with NAFLD, but more studies should be done in this area.